Anuh pharma Limited has received an Income Tax Assessment Order from the Income Tax Department for Assessment Year 2020-21, resulting in a tax demand of ₹78,28,793. The pharmaceutical company disclosed this development to stock exchanges on January 21, 2026, in compliance with SEBI listing regulations.

Assessment Order Details

The Income Tax Department's Assessment Unit issued the order under Section 143(3) read with sections 263 and 144B of the Income Tax Act, 1961. This was followed by a Tax Demand Order under Section 156 of the same Act. The assessment pertains to the scrutiny assessment for Assessment Year 2020-21, covering the financial year 2019-20.

Nature of Tax Demand

The tax demand arose due to disallowances of certain deductions claimed by the company under various provisions of the Income Tax Act. The total amount of ₹78,28,793 includes applicable interest on the disallowed deductions. The company completed the regular assessment process, which resulted in these disallowances being contested by the tax authorities.

Company's Response and Impact Assessment

Anuh Pharma Limited has indicated its intention to challenge the assessment order through proper legal channels. The company plans to file an appeal before Higher Appellate Forums within the prescribed timelines. Management believes it possesses adequate factual and legal grounds to reasonably substantiate its position in the matter.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided details as required under Para A (20) of Part A of Schedule III to the SEBI LODR regulations. The disclosure has also been uploaded on the company's website at www.anuhpharma.com for public access.

The company's shares trade on BSE under scrip code 506260 and on NSE under the symbol ANUHPR in the EQ series. This regulatory filing ensures transparency with stakeholders regarding material developments that could potentially affect the company's operations or financial position.

Anuh Pharma , a leading bulk drug manufacturing company, has reported a significant revenue growth of 21.14% for the first half of fiscal year 2026. The company's revenue increased to Rs 376.73 crores in H1 FY2026, up from Rs 310.98 crores in the same period last year.

Financial Performance

Despite the strong revenue growth, Anuh Pharma's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) remained nearly flat at Rs 75.20 crores, compared to Rs 73.43 crores in H1 FY2025. This indicates that while the company has been successful in expanding its top line, it has faced challenges in maintaining profit margins.

Operational Highlights

Anuh Pharma has recently expanded its manufacturing capacity, which now stands at 2400 MTPA (Metric Tonnes Per Annum) across 9 API (Active Pharmaceutical Ingredient) blocks and 2 intermediate blocks. This expansion is expected to contribute to the company's future growth and operational efficiency.

Future Outlook

The company remains optimistic about its performance in the second half of the fiscal year. Anuh Pharma expects margin recovery in H2 FY2026, driven by two key factors:

1. Operational efficiencies
2. Higher capacity utilization

These improvements are anticipated to help the company leverage its expanded manufacturing capacity more effectively.

Strategic Focus

According to the company's investor presentation, Anuh Pharma's growth strategy focuses on:

1. Market expansion
2. Addition of new products
3. Exploring inorganic growth opportunities

The company is particularly emphasizing innovation and the development of complex chemistry products, with a focus on lifestyle drugs addressing conditions such as diabetes, hypertension, and obesity.

Product Pipeline

Anuh Pharma has a robust pipeline of products under development, including:

• Ticagrelor (Anti-Platelet)
• Linagliptin and Empagliflozin (Anti-Diabetic)
• Pyronaridine Tetraphosphate and Piperaquine Phosphate (Anti-Malarial)
• Vonoprazon Fumarate (Anti-Ulcerative)
• Ethambutol, Pretomanid, and Bedaquiline Fumarate (Anti-TB)

This diverse product pipeline aligns with the company's focus on addressing various therapeutic areas and expanding its market presence.

Long-term Growth Projection

Looking ahead, Anuh Pharma has announced expectations for an annual growth rate ranging between 15% and 16%. This growth projection indicates the company's anticipated business expansion in its operations, leveraging its experienced team and robust resources in Research & Development and marketing.

As Anuh Pharma continues to navigate the challenges of maintaining profitability while expanding its revenue base, investors and industry observers will be keenly watching the company's performance in the second half of FY2026 to see if the expected margin recovery materializes and if the company can achieve its projected growth rate.